تحميل
NASDAQHealthcareMedical - Diagnostics & Research
أحدث البيانات المتاحة
8.42 US$
+0.25 US$ · +3.06%
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
الإغلاق السابق
8.42 US$
+0.25 US$ · +3.06%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
نطاق اليوم
السعر الحالي 8.42 US$
نطاق 52 أسبوعًا
السعر الحالي 8.42 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
72
أقل من القيمة
المشاعر
58
مختلط
المخاطر
78
مخاطر مرتفعة
الزخم
31
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
نطاق اليوم
السعر الحالي 8.42 US$
نطاق 52 أسبوعًا
السعر الحالي 8.42 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 66.58 مليون USD | 55.64 مليون USD | 52.55 مليون USD | 45.56 مليون USD | 48.3 مليون USD |
| تكلفة البضاعة المباعة | 27.78 مليون USD | 22.53 مليون USD | 23.09 مليون USD | 24.21 مليون USD | 20.59 مليون USD |
| الربح الإجمالي | 38.8 مليون USD | 33.11 مليون USD | 29.46 مليون USD | 21.35 مليون USD | 27.71 مليون USD |
| البحث والتطوير | 6.25 مليون USD | 5.38 مليون USD | 4.87 مليون USD | 9.88 مليون USD | 7.24 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 46.62 مليون USD | 41.37 مليون USD | 47.43 مليون USD | 52.02 مليون USD | 44.54 مليون USD |
| نفقات التشغيل | 52.87 مليون USD | 46.75 مليون USD | 52.29 مليون USD | 67.4 مليون USD | 51.78 مليون USD |
| دخل الفوائد | 289 ألف USD | 767 ألف USD | 1.52 مليون USD | 830 ألف USD | 16 ألف USD |
| مصاريف الفوائد | 4.32 مليون USD | 2.23 مليون USD | 2.34 مليون USD | 2.45 مليون USD | 2.63 مليون USD |
| الاستهلاك والإطفاء | 2.12 مليون USD | 1.72 مليون USD | 2.17 مليون USD | 1.56 مليون USD | 948 ألف USD |
| الدخل التشغيلي | −14.07 مليون USD | −13.64 مليون USD | −22.84 مليون USD | −46.05 مليون USD | −24.07 مليون USD |
| صافي الدخل | −19.95 مليون USD | −15.12 مليون USD | −23.69 مليون USD | −47.39 مليون USD | −26.85 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI3.05 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Extended Market ETFVXF1.4 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
iShares Micro-Cap ETFIWC359.52 ألف0.03%1.32 مليار USD0.60%183 US$+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM210 ألف0.18%116.88 مليون USD0.73%15.9402 US$+0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS137.6 ألف0.60%22.76 مليون USD0.20%42.145 US$+1.39%
Dimensional - US Core Equity 2 ETFDFAC53.16 ألف0.00%88.6 مليار USD0.21%45.33 US$+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Core Equity 2 ETFDFACالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
